David Arciniegas
Concepts (417)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries | 40 | 2023 | 493 | 7.290 |
Why?
| | Cognition Disorders | 28 | 2016 | 517 | 3.550 |
Why?
| | Brain Injuries, Traumatic | 14 | 2025 | 358 | 3.080 |
Why?
| | Memory Disorders | 8 | 2024 | 165 | 2.290 |
Why?
| | Neuropsychological Tests | 32 | 2024 | 1066 | 2.160 |
Why?
| | Neuropsychiatry | 6 | 2020 | 17 | 1.970 |
Why?
| | Bipolar Disorder | 11 | 2023 | 270 | 1.930 |
Why?
| | Cholinesterase Inhibitors | 5 | 2024 | 30 | 1.790 |
Why?
| | Neurosciences | 3 | 2017 | 30 | 1.440 |
Why?
| | Mental Disorders | 18 | 2014 | 1083 | 1.340 |
Why?
| | Indans | 2 | 2024 | 11 | 1.330 |
Why?
| | Depressive Disorder, Major | 6 | 2023 | 366 | 1.170 |
Why?
| | Piperidines | 2 | 2024 | 208 | 1.160 |
Why?
| | Crying | 6 | 2014 | 15 | 1.080 |
Why?
| | Consciousness Disorders | 5 | 2023 | 20 | 1.030 |
Why?
| | Mood Disorders | 6 | 2023 | 129 | 1.030 |
Why?
| | Affective Symptoms | 5 | 2014 | 53 | 0.980 |
Why?
| | Brain | 21 | 2023 | 2831 | 0.970 |
Why?
| | Nootropic Agents | 1 | 2024 | 28 | 0.920 |
Why?
| | Frontotemporal Dementia | 2 | 2023 | 56 | 0.910 |
Why?
| | Laughter | 5 | 2014 | 8 | 0.900 |
Why?
| | Aggression | 4 | 2014 | 210 | 0.890 |
Why?
| | Psychotic Disorders | 5 | 2015 | 167 | 0.870 |
Why?
| | Hypoxia-Ischemia, Brain | 3 | 2010 | 37 | 0.850 |
Why?
| | Consciousness | 1 | 2023 | 28 | 0.840 |
Why?
| | Memory | 7 | 2024 | 257 | 0.810 |
Why?
| | Nervous System Diseases | 7 | 2020 | 265 | 0.810 |
Why?
| | Receptors, Cholinergic | 4 | 2011 | 38 | 0.800 |
Why?
| | Humans | 126 | 2025 | 137514 | 0.750 |
Why?
| | Lupus Erythematosus, Systemic | 8 | 2013 | 257 | 0.750 |
Why?
| | Evoked Potentials, Auditory | 6 | 2004 | 181 | 0.720 |
Why?
| | Forensic Psychiatry | 2 | 2013 | 28 | 0.700 |
Why?
| | Psychiatry | 4 | 2016 | 181 | 0.700 |
Why?
| | Antipsychotic Agents | 4 | 2015 | 196 | 0.650 |
Why?
| | Functional Laterality | 8 | 2016 | 229 | 0.650 |
Why?
| | Irritable Mood | 3 | 2022 | 50 | 0.640 |
Why?
| | Hippocampus | 9 | 2019 | 903 | 0.620 |
Why?
| | Alcoholism | 6 | 2022 | 805 | 0.620 |
Why?
| | Hallucinations | 2 | 2016 | 31 | 0.610 |
Why?
| | Psychomotor Performance | 5 | 2011 | 326 | 0.610 |
Why?
| | Diagnosis, Differential | 16 | 2017 | 1486 | 0.610 |
Why?
| | Amnesia | 3 | 2023 | 43 | 0.600 |
Why?
| | Acetylcholine | 4 | 2011 | 186 | 0.600 |
Why?
| | Psychiatric Status Rating Scales | 10 | 2015 | 555 | 0.600 |
Why?
| | Brain Injury, Chronic | 2 | 2013 | 23 | 0.580 |
Why?
| | Autism Spectrum Disorder | 1 | 2023 | 400 | 0.580 |
Why?
| | Confusion | 2 | 2020 | 28 | 0.570 |
Why?
| | Cholinergic Fibers | 3 | 2011 | 18 | 0.560 |
Why?
| | Adult | 50 | 2024 | 37821 | 0.550 |
Why?
| | Diffusion Tensor Imaging | 2 | 2024 | 80 | 0.550 |
Why?
| | Aphasia | 2 | 2015 | 21 | 0.550 |
Why?
| | Severity of Illness Index | 12 | 2011 | 2838 | 0.550 |
Why?
| | Neurology | 2 | 2010 | 114 | 0.530 |
Why?
| | Cognition | 7 | 2018 | 1192 | 0.530 |
Why?
| | Dementia | 3 | 2013 | 252 | 0.520 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 3 | 2014 | 243 | 0.520 |
Why?
| | Attention | 9 | 2019 | 453 | 0.510 |
Why?
| | Capgras Syndrome | 1 | 2016 | 3 | 0.500 |
Why?
| | Politics | 1 | 2017 | 98 | 0.500 |
Why?
| | West Nile Fever | 2 | 2008 | 51 | 0.490 |
Why?
| | Impulsive Behavior | 2 | 2014 | 150 | 0.490 |
Why?
| | Expert Testimony | 2 | 2013 | 39 | 0.480 |
Why?
| | Dopamine Agents | 2 | 2006 | 19 | 0.480 |
Why?
| | Pseudobulbar Palsy | 2 | 2005 | 2 | 0.480 |
Why?
| | Male | 64 | 2024 | 67718 | 0.470 |
Why?
| | Journalism, Medical | 1 | 2015 | 6 | 0.470 |
Why?
| | Brain Concussion | 5 | 2023 | 570 | 0.470 |
Why?
| | Stroke Rehabilitation | 2 | 2005 | 44 | 0.460 |
Why?
| | Connectome | 3 | 2023 | 91 | 0.450 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 2015 | 62 | 0.450 |
Why?
| | Middle Aged | 39 | 2024 | 33355 | 0.430 |
Why?
| | Recovery of Function | 5 | 2019 | 662 | 0.420 |
Why?
| | Double-Blind Method | 6 | 2024 | 1987 | 0.420 |
Why?
| | Psychotropic Drugs | 1 | 2014 | 72 | 0.420 |
Why?
| | Periodicals as Topic | 1 | 2016 | 211 | 0.410 |
Why?
| | Neurotransmitter Agents | 3 | 2008 | 84 | 0.400 |
Why?
| | Mental Status Schedule | 2 | 2010 | 34 | 0.400 |
Why?
| | Electroencephalography | 4 | 2015 | 438 | 0.400 |
Why?
| | Behavioral Symptoms | 1 | 2013 | 42 | 0.390 |
Why?
| | Football | 1 | 2013 | 85 | 0.390 |
Why?
| | Phenylcarbamates | 2 | 2009 | 4 | 0.380 |
Why?
| | Magnetic Resonance Imaging | 19 | 2023 | 3722 | 0.370 |
Why?
| | Treatment Outcome | 14 | 2024 | 10821 | 0.370 |
Why?
| | Schizophrenia | 4 | 2015 | 446 | 0.360 |
Why?
| | Veterans | 4 | 2023 | 1461 | 0.350 |
Why?
| | Neuroprotective Agents | 2 | 2009 | 132 | 0.340 |
Why?
| | Frontal Lobe | 3 | 2013 | 157 | 0.340 |
Why?
| | Female | 48 | 2024 | 73162 | 0.330 |
Why?
| | Capital Punishment | 1 | 2010 | 3 | 0.330 |
Why?
| | Violence | 1 | 2013 | 263 | 0.320 |
Why?
| | Surveys and Questionnaires | 5 | 2023 | 5772 | 0.320 |
Why?
| | Delirium | 2 | 2024 | 85 | 0.320 |
Why?
| | Cerebral Cortex | 5 | 2019 | 459 | 0.320 |
Why?
| | Public Policy | 1 | 2010 | 82 | 0.310 |
Why?
| | Post-Concussion Syndrome | 3 | 2013 | 173 | 0.310 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 2 | 2015 | 81 | 0.310 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2010 | 87 | 0.310 |
Why?
| | Reflex | 1 | 2009 | 69 | 0.300 |
Why?
| | White Matter | 2 | 2024 | 148 | 0.290 |
Why?
| | Insanity Defense | 1 | 2008 | 11 | 0.290 |
Why?
| | Geriatric Assessment | 1 | 2010 | 214 | 0.290 |
Why?
| | Neuroanatomy | 2 | 2023 | 9 | 0.290 |
Why?
| | Dibenzothiazepines | 1 | 2007 | 17 | 0.280 |
Why?
| | Amygdala | 3 | 2018 | 208 | 0.280 |
Why?
| | Crime | 1 | 2008 | 60 | 0.280 |
Why?
| | Injury Severity Score | 5 | 2019 | 525 | 0.280 |
Why?
| | Central Nervous System Stimulants | 4 | 2016 | 161 | 0.280 |
Why?
| | Rivastigmine | 3 | 2021 | 5 | 0.270 |
Why?
| | Alzheimer Disease | 3 | 2011 | 559 | 0.270 |
Why?
| | Cognitive Dysfunction | 2 | 2024 | 386 | 0.270 |
Why?
| | Depression | 4 | 2009 | 1408 | 0.270 |
Why?
| | Stroke | 5 | 2015 | 1129 | 0.270 |
Why?
| | Affect | 4 | 2008 | 310 | 0.260 |
Why?
| | Aged | 16 | 2024 | 23798 | 0.260 |
Why?
| | Military Personnel | 2 | 2023 | 543 | 0.250 |
Why?
| | Executive Function | 2 | 2016 | 457 | 0.250 |
Why?
| | Adrenergic Agents | 1 | 2006 | 6 | 0.250 |
Why?
| | Hiccup | 1 | 2006 | 3 | 0.250 |
Why?
| | Behavioral Sciences | 1 | 2006 | 8 | 0.250 |
Why?
| | Methylphenidate | 3 | 2016 | 38 | 0.250 |
Why?
| | Physician-Patient Relations | 1 | 2010 | 552 | 0.250 |
Why?
| | Clinical Trials as Topic | 2 | 2009 | 1047 | 0.240 |
Why?
| | Hemiplegia | 1 | 2005 | 21 | 0.240 |
Why?
| | Suicide | 1 | 2013 | 646 | 0.240 |
Why?
| | Neuropsychology | 1 | 2006 | 37 | 0.240 |
Why?
| | Paresis | 1 | 2005 | 30 | 0.240 |
Why?
| | Physical Therapy Modalities | 2 | 2005 | 309 | 0.230 |
Why?
| | Amantadine | 1 | 2004 | 7 | 0.230 |
Why?
| | Psychosurgery | 1 | 2004 | 8 | 0.230 |
Why?
| | Neurologic Examination | 5 | 2008 | 113 | 0.230 |
Why?
| | Specialization | 1 | 2006 | 143 | 0.230 |
Why?
| | Indians, North American | 2 | 2010 | 625 | 0.230 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2004 | 21 | 0.230 |
Why?
| | Motor Skills | 1 | 2005 | 101 | 0.220 |
Why?
| | Upper Extremity | 1 | 2005 | 102 | 0.220 |
Why?
| | Disability Evaluation | 3 | 2019 | 291 | 0.220 |
Why?
| | Mental Competency | 1 | 2024 | 26 | 0.220 |
Why?
| | Hospital Mortality | 1 | 2008 | 902 | 0.220 |
Why?
| | Healthy Aging | 1 | 2024 | 35 | 0.210 |
Why?
| | Neuroimaging | 5 | 2019 | 291 | 0.210 |
Why?
| | Stress Disorders, Post-Traumatic | 4 | 2021 | 854 | 0.210 |
Why?
| | Comorbidity | 3 | 2014 | 1618 | 0.210 |
Why?
| | Critical Care | 1 | 2008 | 584 | 0.210 |
Why?
| | Valproic Acid | 2 | 2022 | 47 | 0.200 |
Why?
| | Predictive Value of Tests | 5 | 2019 | 2039 | 0.190 |
Why?
| | Research Design | 1 | 2009 | 1116 | 0.190 |
Why?
| | Analysis of Variance | 5 | 2007 | 1324 | 0.190 |
Why?
| | Myelin Sheath | 1 | 2024 | 171 | 0.190 |
Why?
| | Delusions | 2 | 2015 | 10 | 0.190 |
Why?
| | Magnetoencephalography | 5 | 2011 | 149 | 0.180 |
Why?
| | Regression Analysis | 5 | 2013 | 1029 | 0.180 |
Why?
| | Exercise Therapy | 1 | 2005 | 435 | 0.180 |
Why?
| | Thalamus | 2 | 2018 | 110 | 0.180 |
Why?
| | Emotions | 3 | 2019 | 590 | 0.170 |
Why?
| | Central Nervous System Agents | 1 | 2000 | 5 | 0.170 |
Why?
| | Dominance, Cerebral | 1 | 2000 | 56 | 0.170 |
Why?
| | Electroconvulsive Therapy | 2 | 2014 | 14 | 0.170 |
Why?
| | Mental Status and Dementia Tests | 1 | 2020 | 26 | 0.170 |
Why?
| | Conversion Disorder | 1 | 2020 | 9 | 0.160 |
Why?
| | Rehabilitation Centers | 1 | 2020 | 38 | 0.160 |
Why?
| | Acceptance and Commitment Therapy | 1 | 2020 | 28 | 0.160 |
Why?
| | Physical and Rehabilitation Medicine | 1 | 2020 | 32 | 0.160 |
Why?
| | Brain Diseases | 1 | 2000 | 141 | 0.160 |
Why?
| | Terminology as Topic | 3 | 2025 | 216 | 0.160 |
Why?
| | Adult Survivors of Child Adverse Events | 1 | 2019 | 12 | 0.160 |
Why?
| | Young Adult | 7 | 2024 | 13243 | 0.160 |
Why?
| | Prisoners | 1 | 2021 | 145 | 0.160 |
Why?
| | Chronic Traumatic Encephalopathy | 1 | 2019 | 17 | 0.160 |
Why?
| | Glasgow Coma Scale | 2 | 2011 | 182 | 0.150 |
Why?
| | Sensory Thresholds | 1 | 1999 | 33 | 0.150 |
Why?
| | Habenula | 1 | 2018 | 13 | 0.150 |
Why?
| | Facial Expression | 1 | 2019 | 76 | 0.150 |
Why?
| | Hospitalization | 1 | 2008 | 2197 | 0.150 |
Why?
| | Lithium Compounds | 1 | 2018 | 12 | 0.150 |
Why?
| | Substance-Related Disorders | 2 | 2020 | 1079 | 0.140 |
Why?
| | Prospective Studies | 6 | 2017 | 7598 | 0.140 |
Why?
| | Sertraline | 2 | 2009 | 30 | 0.140 |
Why?
| | Spatial Memory | 1 | 2017 | 26 | 0.140 |
Why?
| | Magnetic Resonance Spectroscopy | 5 | 2013 | 619 | 0.140 |
Why?
| | Suicidal Ideation | 2 | 2023 | 523 | 0.140 |
Why?
| | Biomechanical Phenomena | 2 | 2011 | 768 | 0.130 |
Why?
| | Anxiety Disorders | 2 | 2014 | 376 | 0.130 |
Why?
| | Factor Analysis, Statistical | 1 | 2017 | 287 | 0.130 |
Why?
| | Glutamic Acid | 2 | 2011 | 249 | 0.130 |
Why?
| | Choline | 4 | 2013 | 131 | 0.130 |
Why?
| | Aged, 80 and over | 4 | 2011 | 7593 | 0.130 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2016 | 20 | 0.130 |
Why?
| | Prognosis | 4 | 2019 | 4031 | 0.120 |
Why?
| | Encephalitis | 1 | 2017 | 137 | 0.120 |
Why?
| | Reproducibility of Results | 4 | 2019 | 3292 | 0.120 |
Why?
| | Aspartic Acid | 3 | 2011 | 82 | 0.120 |
Why?
| | Evidence-Based Medicine | 2 | 2011 | 746 | 0.120 |
Why?
| | Suicide, Attempted | 1 | 2018 | 374 | 0.120 |
Why?
| | Behavior, Animal | 1 | 2017 | 514 | 0.110 |
Why?
| | Case-Control Studies | 5 | 2011 | 3546 | 0.110 |
Why?
| | Creatine | 2 | 2011 | 60 | 0.110 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2015 | 153 | 0.100 |
Why?
| | Length of Stay | 2 | 2011 | 1210 | 0.100 |
Why?
| | Leukoencephalopathies | 1 | 2013 | 21 | 0.100 |
Why?
| | Volition | 2 | 2006 | 34 | 0.100 |
Why?
| | Range of Motion, Articular | 2 | 2005 | 392 | 0.100 |
Why?
| | United States | 7 | 2025 | 14696 | 0.100 |
Why?
| | Retrospective Studies | 7 | 2019 | 15628 | 0.100 |
Why?
| | Hyperbaric Oxygenation | 1 | 2012 | 39 | 0.100 |
Why?
| | Blast Injuries | 1 | 2012 | 49 | 0.090 |
Why?
| | Inpatients | 2 | 2018 | 502 | 0.090 |
Why?
| | Referral and Consultation | 3 | 2024 | 780 | 0.090 |
Why?
| | Neurobiology | 1 | 2011 | 16 | 0.090 |
Why?
| | Forensic Medicine | 1 | 2011 | 18 | 0.090 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 106 | 0.090 |
Why?
| | Phenotype | 1 | 1999 | 3205 | 0.080 |
Why?
| | Risk Assessment | 3 | 2011 | 3439 | 0.080 |
Why?
| | Multiple Sclerosis | 2 | 2007 | 454 | 0.080 |
Why?
| | Schizophrenic Psychology | 2 | 2002 | 99 | 0.080 |
Why?
| | Rest | 1 | 2011 | 122 | 0.080 |
Why?
| | Cohort Studies | 4 | 2023 | 5730 | 0.080 |
Why?
| | Antidepressive Agents | 2 | 2018 | 239 | 0.080 |
Why?
| | Delphi Technique | 2 | 2023 | 273 | 0.080 |
Why?
| | Anxiety | 1 | 2017 | 1041 | 0.080 |
Why?
| | Economics | 1 | 2010 | 11 | 0.080 |
Why?
| | Supreme Court Decisions | 1 | 2010 | 11 | 0.080 |
Why?
| | Language Disorders | 1 | 2010 | 36 | 0.080 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 1999 | 34 | 0.080 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2009 | 30 | 0.080 |
Why?
| | Citalopram | 1 | 2009 | 32 | 0.080 |
Why?
| | Capsules | 1 | 2009 | 42 | 0.080 |
Why?
| | International Classification of Diseases | 1 | 2010 | 131 | 0.080 |
Why?
| | Atrophy | 2 | 2007 | 184 | 0.080 |
Why?
| | Time | 1 | 2009 | 82 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2014 | 766 | 0.070 |
Why?
| | Consensus | 2 | 2023 | 685 | 0.070 |
Why?
| | Adolescent | 6 | 2019 | 21555 | 0.070 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2010 | 222 | 0.070 |
Why?
| | Animals | 7 | 2017 | 37011 | 0.070 |
Why?
| | Medical Records | 1 | 2009 | 173 | 0.070 |
Why?
| | Neurochemistry | 1 | 2008 | 7 | 0.070 |
Why?
| | Antibodies | 1 | 2010 | 414 | 0.070 |
Why?
| | Dissociative Disorders | 1 | 2008 | 22 | 0.070 |
Why?
| | Quetiapine Fumarate | 1 | 2007 | 23 | 0.070 |
Why?
| | Presenilin-2 | 1 | 2007 | 5 | 0.070 |
Why?
| | Presenilin-1 | 1 | 2007 | 32 | 0.070 |
Why?
| | Prevalence | 2 | 2021 | 2719 | 0.070 |
Why?
| | Research | 1 | 2011 | 446 | 0.070 |
Why?
| | Receptors, Neurotransmitter | 1 | 2007 | 18 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 3 | 2019 | 2681 | 0.070 |
Why?
| | Interpersonal Relations | 1 | 2010 | 411 | 0.070 |
Why?
| | Wasting Disease, Chronic | 1 | 2007 | 26 | 0.070 |
Why?
| | Intelligence Tests | 1 | 2007 | 59 | 0.070 |
Why?
| | Neurosecretory Systems | 1 | 2007 | 33 | 0.070 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2006 | 10 | 0.070 |
Why?
| | Motor Activity | 2 | 2017 | 723 | 0.070 |
Why?
| | Incidence | 2 | 2011 | 2792 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2009 | 784 | 0.070 |
Why?
| | Pilot Projects | 2 | 2010 | 1703 | 0.070 |
Why?
| | Expressed Emotion | 1 | 2006 | 18 | 0.060 |
Why?
| | Disease Management | 1 | 2010 | 625 | 0.060 |
Why?
| | Gyrus Cinguli | 2 | 2023 | 96 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1950 | 0.060 |
Why?
| | Lithium Carbonate | 1 | 2006 | 5 | 0.060 |
Why?
| | Biogenic Amines | 1 | 2006 | 4 | 0.060 |
Why?
| | Accidents, Traffic | 1 | 2007 | 189 | 0.060 |
Why?
| | Demography | 1 | 2007 | 292 | 0.060 |
Why?
| | Illusions | 1 | 2006 | 14 | 0.060 |
Why?
| | National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2025 | 5 | 0.060 |
Why?
| | Medical History Taking | 1 | 2006 | 119 | 0.060 |
Why?
| | Sex Factors | 2 | 2003 | 2074 | 0.060 |
Why?
| | Disease Progression | 2 | 2011 | 2755 | 0.060 |
Why?
| | Education | 1 | 2006 | 108 | 0.060 |
Why?
| | Restraint, Physical | 1 | 2005 | 72 | 0.060 |
Why?
| | Age Factors | 2 | 2019 | 3301 | 0.060 |
Why?
| | Health Surveys | 1 | 2007 | 520 | 0.060 |
Why?
| | Patient Selection | 1 | 2009 | 691 | 0.060 |
Why?
| | Diazepam | 1 | 2004 | 35 | 0.060 |
Why?
| | Confidence Intervals | 1 | 2005 | 328 | 0.060 |
Why?
| | History, Ancient | 1 | 2004 | 54 | 0.060 |
Why?
| | History, 19th Century | 1 | 2004 | 61 | 0.060 |
Why?
| | Benzodiazepines | 1 | 2006 | 153 | 0.060 |
Why?
| | Probability | 1 | 2005 | 311 | 0.060 |
Why?
| | Narcotics | 1 | 2004 | 52 | 0.060 |
Why?
| | Arm | 1 | 2005 | 106 | 0.060 |
Why?
| | Psychological Tests | 1 | 2005 | 139 | 0.060 |
Why?
| | Hydrocortisone | 1 | 2006 | 318 | 0.060 |
Why?
| | Physostigmine | 1 | 2004 | 12 | 0.050 |
Why?
| | Cognitive Aging | 1 | 2024 | 16 | 0.050 |
Why?
| | Demyelinating Diseases | 1 | 2004 | 88 | 0.050 |
Why?
| | Age of Onset | 1 | 2006 | 522 | 0.050 |
Why?
| | Corpus Callosum | 1 | 2024 | 70 | 0.050 |
Why?
| | Diagnostic Errors | 1 | 2005 | 171 | 0.050 |
Why?
| | Nerve Net | 1 | 2007 | 284 | 0.050 |
Why?
| | Autoantibodies | 1 | 2011 | 1501 | 0.050 |
Why?
| | North America | 1 | 2004 | 313 | 0.050 |
Why?
| | Time Factors | 2 | 2007 | 6817 | 0.050 |
Why?
| | Methadone | 1 | 2004 | 98 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 2095 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2023 | 2857 | 0.050 |
Why?
| | History, 20th Century | 1 | 2004 | 324 | 0.050 |
Why?
| | Akinetic Mutism | 1 | 2003 | 2 | 0.050 |
Why?
| | Electrophysiology | 1 | 2003 | 221 | 0.050 |
Why?
| | Datasets as Topic | 1 | 2023 | 120 | 0.050 |
Why?
| | Cooperative Behavior | 2 | 2006 | 447 | 0.050 |
Why?
| | Anticonvulsants | 1 | 2005 | 218 | 0.050 |
Why?
| | Physician's Role | 1 | 2004 | 206 | 0.050 |
Why?
| | Cerebral Arterial Diseases | 1 | 2003 | 49 | 0.050 |
Why?
| | Hypnotics and Sedatives | 1 | 2004 | 199 | 0.050 |
Why?
| | Auditory Cortex | 1 | 2002 | 43 | 0.050 |
Why?
| | Depressive Disorder | 1 | 2005 | 383 | 0.050 |
Why?
| | Geriatric Psychiatry | 1 | 2002 | 12 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2006 | 306 | 0.050 |
Why?
| | Psychotherapy | 1 | 2003 | 165 | 0.050 |
Why?
| | Coronary Artery Bypass | 1 | 2004 | 238 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2005 | 767 | 0.050 |
Why?
| | Acute Disease | 1 | 2004 | 1008 | 0.050 |
Why?
| | Unconsciousness | 1 | 2001 | 19 | 0.050 |
Why?
| | Social Determinants of Health | 1 | 2025 | 251 | 0.050 |
Why?
| | Health Services for the Aged | 1 | 2002 | 73 | 0.040 |
Why?
| | Chronic Disease | 2 | 2005 | 1790 | 0.040 |
Why?
| | Transdermal Patch | 1 | 2021 | 15 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2005 | 539 | 0.040 |
Why?
| | Myelinolysis, Central Pontine | 1 | 2000 | 2 | 0.040 |
Why?
| | Psychomotor Disorders | 1 | 2000 | 14 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4295 | 0.040 |
Why?
| | Inflammation | 1 | 2011 | 2837 | 0.040 |
Why?
| | Rehabilitation Research | 1 | 2020 | 7 | 0.040 |
Why?
| | Societies, Medical | 2 | 2020 | 820 | 0.040 |
Why?
| | Epilepsies, Partial | 1 | 2000 | 50 | 0.040 |
Why?
| | Prefrontal Cortex | 1 | 2023 | 336 | 0.040 |
Why?
| | Treatment Failure | 1 | 2021 | 353 | 0.040 |
Why?
| | Syndrome | 1 | 2000 | 359 | 0.040 |
Why?
| | Magnetics | 1 | 1999 | 47 | 0.040 |
Why?
| | Glasgow Outcome Scale | 1 | 2019 | 9 | 0.040 |
Why?
| | Happiness | 1 | 2019 | 21 | 0.040 |
Why?
| | Combined Modality Therapy | 2 | 2016 | 1241 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2000 | 148 | 0.040 |
Why?
| | Curriculum | 1 | 2006 | 980 | 0.040 |
Why?
| | Pituitary Gland | 1 | 1999 | 149 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2020 | 132 | 0.040 |
Why?
| | Corpus Striatum | 1 | 2000 | 166 | 0.040 |
Why?
| | Temporal Lobe | 1 | 2019 | 91 | 0.040 |
Why?
| | Social Stigma | 1 | 2020 | 135 | 0.040 |
Why?
| | Reference Values | 1 | 2000 | 821 | 0.040 |
Why?
| | Organ Size | 1 | 2019 | 479 | 0.040 |
Why?
| | Evoked Potentials | 1 | 2019 | 132 | 0.040 |
Why?
| | Reaction Time | 1 | 2000 | 432 | 0.040 |
Why?
| | Follow-Up Studies | 3 | 2018 | 5139 | 0.040 |
Why?
| | Gliosis | 1 | 2017 | 29 | 0.040 |
Why?
| | Maze Learning | 1 | 2017 | 102 | 0.030 |
Why?
| | Patient Discharge | 1 | 2024 | 895 | 0.030 |
Why?
| | Coronary Artery Disease | 1 | 2004 | 703 | 0.030 |
Why?
| | Gray Matter | 1 | 2018 | 83 | 0.030 |
Why?
| | Brain Chemistry | 2 | 2009 | 120 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2019 | 407 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 1999 | 279 | 0.030 |
Why?
| | Mass Screening | 1 | 2005 | 1264 | 0.030 |
Why?
| | Decision Making | 1 | 2024 | 906 | 0.030 |
Why?
| | Models, Animal | 1 | 2017 | 387 | 0.030 |
Why?
| | Fear | 1 | 2019 | 354 | 0.030 |
Why?
| | Astrocytes | 1 | 2017 | 210 | 0.030 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2015 | 45 | 0.030 |
Why?
| | Microglia | 1 | 2017 | 251 | 0.030 |
Why?
| | Academic Medical Centers | 2 | 2010 | 498 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1060 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 851 | 0.030 |
Why?
| | Biomarkers | 2 | 2011 | 4172 | 0.030 |
Why?
| | Software | 1 | 1999 | 670 | 0.030 |
Why?
| | Multivariate Analysis | 2 | 2011 | 1524 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 299 | 0.030 |
Why?
| | Colorado | 3 | 2011 | 4521 | 0.030 |
Why?
| | Aging | 1 | 2024 | 1866 | 0.030 |
Why?
| | Child | 2 | 2019 | 22037 | 0.030 |
Why?
| | Risk Factors | 2 | 2004 | 10356 | 0.020 |
Why?
| | Caregivers | 1 | 2020 | 872 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2004 | 2641 | 0.020 |
Why?
| | Creatinine | 1 | 2013 | 501 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 533 | 0.020 |
Why?
| | Memory, Short-Term | 1 | 2013 | 269 | 0.020 |
Why?
| | Visual Perception | 1 | 2011 | 169 | 0.020 |
Why?
| | Neurofibrillary Tangles | 1 | 2007 | 13 | 0.020 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2007 | 44 | 0.020 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2007 | 73 | 0.020 |
Why?
| | Pituitary Hormones, Anterior | 1 | 2007 | 7 | 0.020 |
Why?
| | Disease Reservoirs | 1 | 2007 | 21 | 0.020 |
Why?
| | Axons | 1 | 2009 | 203 | 0.020 |
Why?
| | Pituitary Gland, Anterior | 1 | 2007 | 39 | 0.020 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2007 | 14 | 0.020 |
Why?
| | Brain Mapping | 1 | 2011 | 610 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2007 | 305 | 0.020 |
Why?
| | Prolactin | 1 | 2007 | 100 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5427 | 0.020 |
Why?
| | Point Mutation | 1 | 2007 | 234 | 0.020 |
Why?
| | Thyrotropin | 1 | 2007 | 114 | 0.020 |
Why?
| | Psychomotor Agitation | 1 | 2007 | 70 | 0.020 |
Why?
| | Introns | 1 | 2007 | 256 | 0.020 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2007 | 142 | 0.020 |
Why?
| | Antiemetics | 1 | 2006 | 47 | 0.020 |
Why?
| | Stereotyping | 1 | 2006 | 46 | 0.020 |
Why?
| | Vomiting | 1 | 2006 | 133 | 0.020 |
Why?
| | Skull | 1 | 2006 | 139 | 0.020 |
Why?
| | Benzamides | 1 | 2006 | 218 | 0.020 |
Why?
| | Mental Processes | 1 | 2005 | 37 | 0.010 |
Why?
| | Verbal Behavior | 1 | 2005 | 46 | 0.010 |
Why?
| | Carbamazepine | 1 | 2005 | 20 | 0.010 |
Why?
| | Mental Health Services | 1 | 2010 | 415 | 0.010 |
Why?
| | MEDLINE | 1 | 2005 | 20 | 0.010 |
Why?
| | Saliva | 1 | 2006 | 242 | 0.010 |
Why?
| | Central Nervous System Diseases | 1 | 2005 | 70 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 658 | 0.010 |
Why?
| | Central Nervous System | 1 | 2005 | 261 | 0.010 |
Why?
| | Hospitals, Veterans | 1 | 2004 | 248 | 0.010 |
Why?
| | Radiography | 1 | 2005 | 834 | 0.010 |
Why?
| | Language | 1 | 2005 | 299 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2066 | 0.010 |
Why?
| | Brain Ischemia | 1 | 2005 | 341 | 0.010 |
Why?
| | Pain | 1 | 2007 | 836 | 0.010 |
Why?
| | Mice | 1 | 2017 | 17843 | 0.010 |
Why?
| | Median Nerve | 1 | 1999 | 23 | 0.010 |
Why?
| | Electric Stimulation | 1 | 1999 | 272 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1999 | 555 | 0.010 |
Why?
|
|
Arciniegas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|